Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

389 - Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)


14 Dec 2018


Poster Display session


Christian Grohe


Annals of Oncology (2018) 29 (suppl_10): x17-x23. 10.1093/annonc/mdy486


C. Grohe1, W. Gleiber2, S. Haas3, H. Mueller-Huesmann4, M. Schulze5, J. Atz6, R. Kaiser6

Author affiliations

  • 1 Department Of Pneumology, ELK Berlin, 13125 - Berlin/DE
  • 2 Pneumology/allergology, University Hospital Frankfurt, Frankfurt/DE
  • 3 Clinics For Haematology, Oncology And Nephrology, Friedrich-Ebert Hospital Neumuenster, 24534 - Neumuenster/DE
  • 4 Klinik Für Hämatologie Und Onkologie, Bruederkrankenhaus St. Josef, 33098 - Paderborn/DE
  • 5 Praxis, Dr. Schulze, 02763 - Zittau/DE
  • 6 Medical Affairs Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 - Ingelheim am Rhein/DE


Abstract 389


Nintedanib (Vargatef®), an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors, is approved in the EU and other countries for treatment of locally advanced or metastatic NSCLC of adenocarcinoma histology in combination with docetaxel after 1st line chemotherapy. Data are scarce regarding efficacy and safety of nintedanib in NSCLC pts who had been pre-treated with ICIs.


This interim analysis is part of this ongoing trial and included 22 treated pts with locally advanced or metastatic lung adenocarcinoma who received nintedanib and docetaxel in 3rd line following ICIs in 2nd line.


Median age was 58 years (range: 45 – 76); 15/22 pts (68.2%) were men, 9/22 pts (40.9%) were ECOG PS0/1, 4/22 pts (18.2%) had brain metastases, and 19/22 pts (86.4%) were current or former smokers. 1st line chemotherapy included pemetrexed (15/22 pts, 68.2%), carboplatin (12/22 pts, 54.6%), cisplatin (12/22pts, 54.6%), bevacizumab (6/22 pts, 27.3%), vinorelbine (4/22 pts, 18.2%), paclitaxel (2/22 pts, 9.1%), and docetaxel (1/22 pts, 4.4%). 2nd line treatment included nivolumab (17/22 pts, 77.3%) and pembrolizumab (5/22 pts, 22.7%). Under nintedanib and docetaxel, 7/12 pts (58.3%) showed a partial response, and 3/12 pts (25.0%) showed stable disease, resulting in a DCR of 83.3% (10/12 pts). Median PFS was 5.5 months (95%CI 1.9 – 8.7). Treatment emergent adverse events (TEAEs) grade ≥3, serious TEAEs, and TEAEs leading to discontinuation occurred in 13/22 pts (59.1%), 11/22 pts (50.0%), and 7/22 pts (31.8%), respectively.


Nintedanib, in combination with docetaxel, showed clinically meaningful efficacy and an acceptable safety profile in a limited number of stage IIIB/IV lung adenocarcinoma patients following chemotherapy and ICIs. Larger studies are warranted to further explore the potential of nintedanib and docetaxel in this novel setting supporting anti-angiogenesis plus docetaxel as a subsequent therapeutic principle in patients progressing under ICI therapy.

Editorial acknowledgement

Clinical trial identification


Legal entity responsible for the study

Boehringer Ingelheim Pharma GmbH & Co. KG.


Boehringer Ingelheim Pharma GmbH & Co. KG.


W. Gleiber: Membership on an advisory board. J. Atz, R. Kaiser: Employee of Boehringer Ingelheim Pharma GmbH & Co KG. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.